^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Venclexta (venetoclax) (Bcl2 inhibitor) + Nailike (olverembatinib) (Bcr-abl tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
827 Olverembatinib Combined with Venetoclax and Reduced-Intensity Chemotherapy for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Early Results from a Phase II Study
Published date:
11/02/2023
Excerpt:
The combination of olverembatinib and venetoclax with reduced-intensity chemotherapy is a safe and effective regimen in patients with newly diagnosed Ph+ ALL. The regimen results in high rates of CMR in the absence of intensive chemotherapy or immunotherapy.
Trial ID:
